Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05767021 · ClinicalTrials.gov registry record · Phase 3

A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 3 study of Ulcerative Colitis and Ulcerative Colitis Chronic, sponsored by Eli Lilly and Company.

Active
Registry status
Phase 3
Development phase
172
Enrollment target
20
Study locations

NCT05767021 is a Phase 3 study of Ulcerative Colitis and Ulcerative Colitis Chronic that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 172 participants, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05767021, a Phase 3 study of Ulcerative Colitis and Ulcerative Colitis Chronic, is active but no longer recruiting, sponsored by Eli Lilly and Company.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
172 participants
Enrollment target
20
Study locations

Study Summary

A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.

Conditions Studied

Ulcerative Colitis Ulcerative Colitis Chronic

Interventions

  • DRUG Mirikizumab

Study Locations (20)

Florida

  • Central Florida Gastro Research - Clearwater
  • Encore Borland-Groover Clinical Research - Jacksonville
  • Research Associates of South Florida - Miami
  • Advanced Research Associates, LLC - Miami
  • GCP Clinical Research, LLC - Tampa
  • International Center for Research LLC - Tampa

California

  • Om Research, LLC - Lancaster
  • California Medical Research Associates, Inc. - Northridge
  • Clinical Applications Laboratories, Inc. - San Diego

Arizona

  • Dedicated Clinical Research - Litchfield Park
  • Arizona Digestive Health - Sun City - Sun City

Georgia

  • Digestive Healthcare of Georgia - Atlanta
  • Atlanta Center for Gastroenterology, P.C. - Decatur

Indiana

  • IU Health University Hospital - Indianapolis
  • Gastroenterology Health Partners - New Albany

Louisiana

  • GI Alliance/ Metairie - Metairie
  • Delta Research Partners - Monroe

Connecticut

  • Medical Research Center of Connecticut, LLC - Hamden

Idaho

  • Grand Teton Research Group, PLLC - Idaho Falls

Trial Details

FieldValue
Enrollment Target 172 participants
Start Date 2023-05-17
Est. Completion 2026-04
Phase Phase 3

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05767021

The ClinicalTrials.gov registry entry for NCT05767021 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (92% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Ulcerative Colitis appearing as the primary indexed condition, and to 1 intervention - of which Mirikizumab is the first listed.

NCT05767021 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT05767021 about?

NCT05767021 is a clinical study titled "A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis". A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.

What is the current status of trial NCT05767021?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 172 participants. The study started on 2023-05-17. Estimated completion is 2026-04.

What conditions does trial NCT05767021 study?

This clinical trial studies the following conditions: Ulcerative Colitis, Ulcerative Colitis Chronic.

What interventions are being tested in trial NCT05767021?

The interventions under investigation include: Mirikizumab (DRUG).

Who is sponsoring clinical trial NCT05767021?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05767021 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ulcerative Colitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ulcerative Colitis

All registered trials for this condition

Ulcerative Colitis Chronic

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.